^
Association details:
| Biomarker: | SF3B1 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
030 | GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL
Published date:
06/09/2021
Excerpt:
For GClb del(17p) (HR 3.2, p < 0.001), del(11q) (HR 1.8, p < 0.01), unmutated IGHV (HR 3.1, p < 0.0001) and mutations in ATM (HR 1.8, p = 0.01), BIRC3 (HR 3.0, p < 0.01), NOTCH1 (HR 1.7, p < 0.01), NOTCH1 minor (HR 2.1, p = 0.02) and SF3B1 (HR 1.6, p = 0.03) were associated with short PFS...
Secondary therapy:
chlorambucil
DOI:
https://doi.org/10.1002/hon.2879
Trial ID:
Source:
Title:
GENETIC MARKERS AND OUTCOME IN FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL
Published date:
05/12/2021
Excerpt:
…gene mutations in the CLL14 trial comparing obinutuzumab + chlorambucil (GClb) vs. obinutuzumab + venetoclax (VenG) in 432 patients (1:1) with CIRS>6 and/or creatinine clearance < 70 ml/min….For GClb del(17p) (HR 3.2, p<0.001), del(11q) (HR 1.84, p<0.01) and mutations in ATM (HR 1.8, p=0.01), BIRC3 (HR 3.0, p<0.01), NOTCH1 (HR 1.7, p<0.01) and SF3B1 (HR 1.6, p=0.03) were associated with short PFS…
Secondary therapy:
chlorambucil
Trial ID:
